Form 4: Vanda Pharmaceuticals SVP, CFO & Treasurer Kevin Patrick Moran Reports Acquisition of 125,000 Shares

Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, reports acquiring 125,000 shares of common stock via a restricted stock unit award.

Summary

• Kevin Patrick Moran, the SVP, CFO & Treasurer of Vanda Pharmaceuticals, filed a Form 4.
• The report indicates that Mr. Moran acquired 125,000 shares of Vanda Pharmaceuticals common stock on February 18, 2025.
• These shares were acquired through a time-based restricted stock unit (RSU) award.
• The RSU vests in four equal annual installments, starting on March 1, 2026, contingent upon continuous employment.
• Vested shares will be delivered on the First Permissible Trading Day after each vesting date.
• Following the reported transaction, Mr. Moran directly owns 353,763 shares of common stock.
• Mr. Moran also indirectly owns 635 shares of common stock through his wife.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to stock options vesting. The acquisition of shares by an executive is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSU award is contingent upon Mr. Moran's continued employment with Vanda Pharmaceuticals.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and their executives, providing transparency into insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.

Key Dates

Keywords

Form 4, Vanda Pharmaceuticals, Kevin Patrick Moran, Insider Trading, Beneficial Ownership, Restricted Stock Units, VNDA, SVP, CFO & Treasurer